Columbia University Medical Center

Intensive Blood Pressure Control Is Worth Extra Cost, Suggests Study

By preventing future cardiac events, lowering systolic blood pressure to 120 mmHg in high-risk patients is cost-effective

Source: Getty Images

New York, NY (Aug. 23, 2017)—Intensive blood pressure control—targeting a systolic blood pressure of 120 mmHg or less versus the standard target of 140 mmHg—comes with higher up-front costs, but a new study from researchers at NewYork-Presbyterian/Columbia University Medical Center and the University of Utah shows that the benefits—fewer cardiac events—outweigh those costs in the long term.

The study was published online today in the New England Journal of Medicine.

Previously, investigators from the systolic blood pressure intervention trial (SPRINT) reported in the same journal that intensive therapy lowered rates of death and cardiovascular events compared with standard treatment in 9,361 older adults (age 75 or older) with high blood pressure and other heart disease risk factors.

“An estimated 17 million older adults in the U.S. have the same risk factors as those in the SPRINT trial and stand to benefit from intensive blood pressure control,” said Andrew Moran, MD, MPH, the Herbert Irving Assistant Professor of Medicine at Columbia, a physician at NewYork-Presbyterian, and a senior author of the paper. “But is the additional cost of intensive therapy, which may include extra trips to the doctor’s office, multiple medications, and possibly more side effects from those medications, a good value for both insurers and patients?”

To answer that question, Dr. Moran and colleagues from the SPRINT Economics Working Group used a model to simulate intensive and standard treatment in 10,000 hypothetical SPRINT-eligible patients. The model incorporated 250 variables, including a wide range of health histories and adverse side effects, to arrive at a real-life estimate of the benefits and costs of intensive therapy.

Intensive blood pressure control was found to cost less than $50,000 for each quality-adjusted year of life gained (a commonly accepted willingness-to-pay threshold). But 10 to 20 years later, the extra expenses would be offset by the cardiac events and related treatment costs prevented by intensive treatment.

A second study, led by researchers at the Rogers Memorial Veterans Hospital in Bedford, Mass., and published in the same issue of the journal, showed that SPRINT participants on intensive therapy were as satisfied with their care as those on standard therapy despite the additional medications and doctor visits.

“Intensive blood pressure treatment prevents heart disease, but it requires extra effort from patients and health care providers,” said Dr. Moran. “Our study showed that it is a very good value if the treatment is sustained long term. These findings, in combination with the evidence that adhering to multiple antihypertensive medications does not affect health-related quality of life, suggest that the intensive treatment approach could be used more widely in patients at high risk for heart disease.”

###

The study is titled “Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control.” A complete list of authors may be found in the paper.

 

The authors report no financial or other conflicts of interest.

 

The study was supported by grants from the National Institutes of Health (1K01HL133468-01, R01 HL130500-01A1, and U54-GM10494).

Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. The campus that Columbia University Medical Center shares with its hospital partner, NewYork-Presbyterian, is now called the Columbia University Irving Medical Center. For more information, visit cumc.columbia.edu or columbiadoctors.org.

NewYork-Presbyterian

NewYork-Presbyterian is one of the nation’s most comprehensive, integrated academic healthcare delivery systems, whose organizations are dedicated to providing the highest quality, most compassionate care and service to patients in the New York metropolitan area, nationally, and throughout the globe. In collaboration with two renowned medical schools, Weill Cornell Medicine and Columbia University Medical Center, NewYork-Presbyterian is consistently recognized as a leader in medical education, groundbreaking research and innovative, patient-centered clinical care.

NewYork-Presbyterian has four major divisions:

  • NewYork-Presbyterian Hospital is ranked #1 in the New York metropolitan area by U.S. News and World Report and repeatedly named to the Honor Roll of “America’s Best Hospitals.”
  • NewYork-Presbyterian Regional Hospital Network comprises hospitals and other facilities in the New York metropolitan region.
  • NewYork-Presbyterian Physician Services, which connects medical experts with patients in their communities.
  • NewYork-Presbyterian Community and Population Health, encompassing ambulatory care network sites and community healthcare initiatives, including NewYork Quality Care, the Accountable Care Organization jointly established by NewYork-Presbyterian Hospital, Weill Cornell Medicine and Columbia.

For more information, visit www.nyp.org and find us on Facebook, Twitter and YouTube.